1. Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era.
- Author
-
Li, Xian, Zhao, Aiqi, Jiang, Huifang, Lu, Ying, Le, Jing, Xie, Yaping, Hu, Meiwei, Zeng, Hui, Zhao, Jianzhi, Zhou, Mei, Zhou, Hui, Chen, Lili, Zhu, Weiguo, Ouyang, Guifang, Qiu, Huiqing, Jiang, Songfu, Guo, Qunyi, Qian, Wenbin, and Liang, Yun
- Subjects
COVID-19 ,HEMATOLOGIC malignancies ,CHINESE people ,SARS-CoV-2 Omicron variant ,COVID-19 pandemic - Abstract
Patients with hematologic malignancies are often immunodeficient and therefore have a higher risk of severe symptoms from coronavirus disease 2019 (COVID-19). We retrospectively examined a cohort of 289 patients from 16 hospitals in Zhejiang Province who had hematologic malignancies and COVID-19 during a period when the Omicron variant was predominant. Univariate analysis showed that some clinical characteristics, including elder age (P = 0.014), multiple comorbid conditions (P = 0.011), and receipt of active antineoplastic therapy (P = 0.018) were associated with an increased risk of severe COVID-19. Patients with severe/critical COVID-19 had significantly lower levels of lymphocytes and serum albumin, and significantly higher levels of D-dimer, lactate dehydrogenase, C-reactive protein, and interleukin-6 (all P < 0.05). Fifty-four patients (18.7%) had symptoms lasting ≥3 weeks, suggesting that persistent long-term COVID-19 infection is likely present in a significant proportion of patients. Receipt of the inactivated vaccine was unrelated to disease severity (P = 0.143), which indicated that many patients with hematologic malignancies may not have effective humoral immunity to inactivated vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF